Intended for healthcare professionals

Letters FDA on rosiglitazone

More on advisory committee decision

BMJ 2010; 341 doi: (Published 07 September 2010) Cite this as: BMJ 2010;341:c4868
  1. David J Graham, medical officer1,
  2. Kate Gelperin, medical officer1
  1. 1Office of Surveillance and Epidemiology, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA
  1. david.graham1{at}

    Your readers may be interested in additional background concerning the recent US Food and Drug Administration (FDA) advisory committee meeting on rosiglitazone.1 In July 2007 a joint meeting of two FDA advisory committees voted 20-3 that rosiglitazone increased the risk of acute myocardial ischaemia and 22-1 that rosiglitazone remain on the market, without ever describing the drug’s benefits or explaining how they exceeded its cardiovascular risks. …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription